
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. has demonstrated a positive financial outlook through the upward revision of its fiscal year 2026 EPS estimate to $(4.17), indicating improved expectations for the company's financial performance compared to the previous estimate of $(8.63). The anticipated approval of the MyoVista device, along with the rollout of the MyoVista Insights cloud software platform and the expected FDA approval of its first diagnostic algorithm in the first half of 2026, positions the company for significant market opportunities in the cardiac diagnostic field. Additionally, the company's reaffirmation of regulatory timelines highlights its commitment to achieving critical milestones that could enhance its competitive edge in the growing healthcare sector.
Bears say
HeartSciences Inc. faces multiple fundamental challenges that contribute to a negative outlook on its stock, including significant balance sheet and liquidity risks. The company's future revenue projections for FY2026 have been drastically reduced from $1.2 million to only $0.1 million, primarily due to delays in obtaining FDA regulatory approvals. Additionally, the company's reliance on successful clinical trials and commercialization of its AI-ECG diagnostic solutions highlights potential vulnerabilities amidst increasing competition and fluctuating investor sentiment in the healthcare sector.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares